

Date: 24.05.2024

To,
BSE Limited
The Compliance Department of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 531592

Subject: Outcome of the Meeting of Board of Directors held on Friday, May 24, 2024 at 03.00 P.M.

Dear Sir/ Madam,

With reference to the captioned subject and Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Board of Directors of the Company at its meeting held on today, i.e. Friday, May 24, 2024, inter alia, considered and approved:

1. The Audited Standalone & Consolidated Financial Statements of the Company for the Financial Year ended 31st March, 2024;
2. The Audited Standalone & Consolidated Financial Results of the Company for the Quarter and Financial Year ended 31st March, 2024;
3. Taken on record the report of the Auditors on standalone and consolidated Financial Statements;

The declaration that the Report of the Statutory Auditors is with unmodified opinion with respect to Standalone & Consolidated Audited Financial Results for the quarter and year ended 31st March, 2024 is attached herewith.

4. The appointment of M/s. Jaymin Modi & Co., Practicing Company Secretaries, as Secretarial Auditor for the financial year 2024-2025;
5. The appointment of M/s. Bilimoria Mehta and Co., Chartered Accountant as Internal Auditor of the Company pursuant to Section 138 of the Company Act, 2013 and rules made there under for the financial year 2024-2025;
6. The appointment of M/s. Nuren Lodaya & Associates., Practicing Company Secretary, for issuing Annual Secretarial Compliance Report under Reg. 24A of SEBI (LODR) Reg., 2015 for the financial Year 2023-2024.



GENPHARMASEC LIMITED

Additionally the details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 and brief profile is attached herewith as Annexure-A, Annexure- B and Annexure- C.

Copies of Audited Standalone & Consolidated Financial Results of the Company for the Quarter and Financial Year ended 31st March, 2024 along with report of the Auditors thereon are attached herewith.

We further inform you that the Board Meeting commenced at 3:00 p.m. today and concluded at 11:15 p.m.

Kindly take the same on records for your perusal.

Thanking you,

Yours faithfully,


For and behalf of the Board of Director of,
Genpharmasec Limited

SOHAN
CHATURVEDI

Digitally signed by
SOHAN CHATURVEDI
Date: 2024.05.24
23:17:22 +05'30'



Mr. Sohan Chaturvedi
Whole time director & CFO
DIN- 09629728

 104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc
Ltd., Akurli Road, Kandivali (East), Mumbai 400101.

 +91-86555 50242

 compliance@genpharmasec.com
info@genpharmasec.com

 www.genpharmasec.com



ANNEXURE 1

Appointment of M/s. Jaymin Modi & Co., Practicing Company Secretaries, as the Secretarial Auditor of the Company.

Sr. No.	PARTICULARS	DISCLOSURES
1.	Name of the Internal Auditor	M/s Jaymin Modi & Co.
2.	Reason for appointment	Appointment: to Comply with the Companies Act, 2013. and the requirements under SEBI (LODR) Amendment Regulations, 2015
3.	Date of appointment & term of appointment	24.05.2024
4.	Brief profile	Jaymin Modi & Co. is Practicing Company Secretaries firm registered with the Institute of Company Secretaries of India (ICSI), providing quality services in the Corporate Law field. Jaymin Modi & Co has extensive knowledge and experience in dealing with matters relating to Company Law, Securities Laws – Initial Public Offers, Direct Listing, Secretarial Due Diligence, Listings and Capital Market Transactions, Jaymin Modi is an Associate member of Institute of Company Secretaries of India and a Commerce and Law graduate from Mumbai University. He has more than 10 years of experience in the field of Corporate Law and more than 8 years of practice experience as a Practicing Company Secretary. He provides advisory in array of field of corporate laws related matters through his firm.
5.	Disclosure of relationships between directors	Not Applicable

ANNEXURE 2

Appointment of M/s. Bilimoria Mehta and Co., Chartered Accountants, as the Internal Auditor of the Company.

Sr. No.	PARTICULARS	DISCLOSURES
1.	Name of the Internal Auditor	M/s. Bilimoria Mehta and Co.
2.	Reason for appointment	Following the provisions of Section 138 of the Companies Act, 2013 read with Rule 13 of the Companies (Accounts) Rules, 2014 and other applicable provisions (if any) of the Companies Act, 2013 the Company has appointed an Internal Auditor for conducting Internal Audit of the Company.
3.	Date of appointment & term of appointment	24.05.2024
4.	Brief profile	Bilimoria Mehta & Co (“BMC”) was established in 1977. Over the years, BMC has created a niche for itself in the fields of Audit & Assurance, Direct & Indirect Tax Consultancy, Advisory on Corporate



GENPHARMASEC LIMITED

		Laws, FEMA, Management Consultancy, etc. We serve a wide arena of clientele across various industries including Manufacturing, Trading, Banking & Finance, Insurance & Automobile sector Dedicated team of Qualified Chartered Accountants to deliver quality solutions customized to the needs of the clients.
5.	Disclosure of relationships between directors	Not Applicable

ANNEXURE 3

Appointment of M/s. Nuren Lodaya & Associates, Practicing Company Secretary, for issuing Annual Secretarial Compliance Report under Reg. 24A of SEBI (LODR) Reg., 2015 for the financial Year 2023-2024.

Sr. No.	PARTICULARS	DISCLOSURES
1.	Name of the Auditor	M/s. Nuren Lodaya & Associates
2.	Reason for appointment	Appointment: to Comply with the Companies Act, 2013 and the requirements under SEBI (LODR) Amendment Regulations, 2015
3.	Date of appointment & term of appointment	24.05.2024
4.	Brief profile	CS Nuren Lodaya & Associates has been a guiding force in the legal and corporate advisory landscape, with a rich experience spanning more than 7 years. CS Nuren Lodaya is not only a distinguished Company Secretary but also a seasoned Trademark Attorney, bringing a wealth of knowledge to the firm. Leading a proficient team for over 5 years, CS Nuren Lodaya specializes in Start-up Investment Round Advisory, ensuring compliance with the Companies Act, 2013, LLP Act, 2008, and SEBI regulations.
5.	Disclosure of relationships between directors	Not Applicable



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander (East), Dist – Thane, Maharashtra- 401105

Mob 9029326651, Email: caabhishek2012@gmail.com

INDEPENDENT AUDITOR’S REPORT

To
The Board of Directors
GENPHARMASEC LIMITED
(Formerly known as ‘Generic Pharmasec Limited’)

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of standalone financial results of **GENPHARMASEC LIMITED (Formerly known as ‘Generic Pharmasec Limited’)** for the quarter and year ended 31st March, 2024 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”)

In our opinion and to the best of our information and according to the explanations given to us these financial results:

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

(ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended as well as for the year to date results for the period from 1.4.2023 to 31.03.2024

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (“the Act”). Our responsibilities under those Standards are further described in the auditor’s responsibilities for the audit of the financial results section of our report. We are independent of the Company in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management’s responsibility for the Standalone Financial Results



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander (East), Dist –Thane, Maharashtra-401105

Mob 9029326651, Email: caabhishek2012@gmail.com

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the annual financial statements. The Company's Management and Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other Accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial result that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of directors are responsible for overseeing the Company's financial reporting process.

Auditor's responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander (East), Dist –Thane, Maharashtra-401105

Mob 9029326651, Email: caabhishek2012@gmail.com

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the operating effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander (East), Dist - Thane, Maharashtra-401105

Mob 9029326651, Email: caabhishek2012@gmail.com

Other Matters

The Statement includes the standalone financial results for the quarter ended 31st March, 2024 being the balancing figures between audited figures in respect of the financial year ended 31st March, 2024 and the published unaudited year to date figures upto 31st December, 2023, being the date of the end of the third quarter of the current financial year, which were subject to limited review by us, as required under the Listing Regulations.

For Abhishek S Tiwari & Associates
Chartered Accountants
FRN: 141048W



Abhishek Tiwari
Partner
M.No.155947
Place : Mumbai
Date: 24.05.2024
UDIN: 24155947BKCAXG8049

*** GENPHARMASEC LIMITED**
(FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)
Statement of Standalone Audited Financial Results for the Quarter & Year Ended 31st March, 2024

(Rs. In Lakhs)

Particulars	Quarter Ended			Year Ended	
	31/03/2024	31-12-2023	31/03/2023	31/03/2024	31/03/2023
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1 Revenue from Operations	1,019.85	638.45	621.65	3,040.57	2,551.57
2 Other Income	31.09	14.25	5.80	71.76	10.01
3 Total Revenue (1 + 2)	1,050.94	652.71	627.44	3,112.33	2,561.58
4 Expenses					
Purchase of stock-in-trade	769.05	393.96	630.14	2,339.92	2,318.40
Changes in inventories of finished goods, work-in-progress and stock-in-trade	49.41	104.62	(99.26)	83.33	21.34
Employee benefits expense	16.21	23.46	16.89	76.42	53.67
Finance Cost	14.22	12.45	5.60	39.46	5.60
Depreciation and amortisation expense	0.42	0.47	0.60	1.67	1.97
Other expenses	168.95	114.76	53.23	524.85	132.45
Total expenses	1,018.27	649.72	607.22	3,065.67	2,533.42
5 Profit/(Loss) Before Exceptional item and Tax (3-4)	32.67	2.98	20.24	46.66	28.16
6 Exceptional items	-	-	-	-	-
7 Profit/(Loss) Before Tax (5-6)	32.67	2.98	20.24	46.66	28.16
8 Tax expense					
(1) Current Tax	-	-	-	-	-
(2) Deferred Tax	(37.81)	3.39	84.32	(42.02)	84.32
(3) Prior Period Tax	-	(0.03)	-	(0.03)	-
9 Profit / (Loss) from continuing operations	(5.14)	6.34	104.56	4.62	112.48
10 Profit / (Loss) from discontinuing operations	-	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-	-
12 Profit/(loss) from Discontinuing	-	-	-	-	-
13 Profit (Loss) for the period (9+12)	(5.14)	6.34	104.56	4.62	112.48
14 Other Comprehensive income;					
A (i) Items that will not be reclassified to profit or loss					
Equity Instruments through FVOCI	30.71	28.87	(14.32)	(73.04)	(116.40)
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will	-	-	-	-	-
15 Total Comprehensive Income for the period (13+14) (Comprising profit/ (loss) and other Comprehensive Income for the	25.57	35.21	90.24	(68.42)	(3.92)
16 Paid-up Equity Share Capital (Face value of equity share is Rs.1/- each)	5,537.20	2,768.60	2,768.60	5,537.20	2,768.60
Other Equity				919.57	(1,235.56)
17 Earnings per equity share (for discontinued & continuing operations) of face value of Rs. 10 each					
(a) Basic	(0.00)	0.00	0.04	0.00	0.04
(b) Diluted	(0.00)	0.00	0.04	0.00	0.04

Notes:

- 1 The Financial result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 24th May, 2024.
- 2 The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.
- 3 The audited report does not contain any qualification. The above Financial audited review report will be filed with the stock Exchange and will also be available on Company's website www.genpharmasec.com
- 4 Segment Reporting has been annexed in Annexure 1.
- 5 The certificate of CFO in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the above results has been placed before the Board of Directors
- 6 The outstanding loan of Rs. 41.96 Lacs as on 31.03.24, have been provided as bad debts by the company and is included under the head 'Other Expenses' for the quarter and year ended 31.3.24.
- 7 The results for the quarter ended 31st March,2024 and 31st March,2023 are the balancing figure between audited figures in respect of the full financial year and the published unaudited financial results of the nine months ended 31st December ,2023 and 31st December,2022 respectively.
- 8 The Name of the company has been changed from Generic Pharmasec Limited to Genpharmasec Limited w.e.f 25th October,2021
- 9 The company has incorporated a new wholly owned subsidiary namely M/s. Clinigenome India Pvt Ltd' to expand the business activities on 29.01.2024
- 10 The Company has recognised the Deferred Tax Assets of Rs. 42.50 Lacs on Carried forward unabsorbed Depreciation Loss of Rs.184.50 Lacs as per income tax records on the bases of managemnet estimate of virtual certainty of Profit in future.
- 11 During the quarter ended 31st March, 2024; the company made investment in M/s. Derron Healthcare Pvt Ltd, (DHPL) as detailed hereunder:

The Company has entered into an Share Purchase Agreement (SPA) with DHPL and its promoters on 19th September 2023 for acquiring 70% shareholding of DHPL. The Company has also simultaneously entered into a Share Subscription Cum Shareholder's Agreement' (SSSA) on the same day to and agreed to induct Rs. 5 Crores into DHPL and in turn, DHPL will allot 13,84,275 shares to the Company.

The Company made payment of Rs. 12,63,95,377/- to one of the Promoters, Mr. Vibhava Kumar Singh who is holding 70% shares in DHPL for purchase of 35,00,000 shares. The Company has also inducted Rs. 5 crore in DHPL for subscription of 13,84,275 shares. These payments represent full payment towards total acquisition of 70% shareholding In DHPL and additional shareholding as envisaged in SSSA.

The total acquisition is to be completed by 19th September 2024. However, M/s. Genpharmasec Ltd, the company, will gain 'controlling interest' only after complete execution of respective SPA and SSA.
- 12 The Board of Directors at its meeting held on 21st February 2024 allotted 27,68,59,850 shares to the Equity Shareholders of the Company through Right issue at issue price of Rs. 1.75 per equity Share (including a premium of Rs. 0.75 per equity Share).

For and on behalf of the Board of
Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)

Sohan

Sohan Chaturvedi

(WHOLE TIME DIRECTOR & CFO)

DIN : 09629728



PLACE : MUMBAI

Date :24.05.2024

GENPHARMASEC LIMITED
(FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)
Statement of Standlone Audited Assets & Liability as at 31st March, 2024

(Amount in Lakhs)

Particulars	As At 31st March 2024	As At 31st March 2023
Assets		
(1) Non-Current Assets		
(A) Property, Plant And Equipment	10.16	10.00
(B) Financial Assets	-	-
(I) Investments	1,783.69	-
(II) Loans	1,207.22	-
(III) Others	-	-
(C) Deferred Tax Asset (Net)	42.60	84.61
Total Non-Current Assets	3,043.68	94.61
(2) Current Assets		
(A) Inventories	884.22	967.55
(B) Financial Assets	-	-
(I) Investments	168.39	95.35
(II) Trade Receivables	909.99	570.92
(III) Cash And Cash Equivalents	291.67	39.76
(IV) Bank Balance Other Than (iii) Above	1,566.20	159.55
(V) Loans	0.69	48.13
(C) Current Tax Assets (Net)	4.94	0.76
(D) Other Current Asset	177.70	10.90
Total Current Assets	4,003.78	1,892.92
Total Assets	7,047.46	1,987.53
Equity And Liabilities		
Equity		
(A) Equity Share Capital	5,537.20	2,768.60
(B) Other Equity	919.57	(1,235.56)
Total Of Equity	6,456.77	1,533.04
Liabilities		
(1) Non-Current Liabilities		
(A) Financial Liabilities		
(I) Borrowings	321.04	248.12
Total Non-Current Liabilities	321.04	248.12
(2) Current Liabilities		
(A) Financial Liabilities		
(I) Borrowings	-	60.08
(II) Trade Payables	-	-
A) Total Outstanding Dues Of Micro Enterprises And Small	11.73	
B) Total Outstanding Dues Of Creditors Other Than Micro E	226.06	137.00
(B) Other Current Liabilities	31.86	9.29
Total Current Liabilities	269.65	206.37
Total Equity And Liabilities	7,047.46	1,987.53

For and on behalf of the Board
GENPHARMASEC LIMITED
(FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)

Sohan
Sohan Chaturvedi
(WHOLE TIME DIRECTOR & CFO)
DIN : 09629728



Place: Mumbai
Date :24.05.2024

GENPHARMASEC LIMITED

(FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)

Cash Flow Statement for the year ended 31st March, 2024

(Amount in Lakhs)

PARTICULARS	For the year ended 31st March 2024	For the year ended 31st March 2023
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit /(Loss) before tax and Extra Ordinary items	46.66	28.16
Adjustment for:-		
Depreciation	1.67	1.97
FVOCI	(73.04)	-
Interest Expenses	37.45	-
Interest Income	(40.30)	-
Interest on FD measured at Amortised cost	(13.15)	(2.27)
Interest income on income tax refund	(0.03)	(0.80)
Baddebts	41.96	6.97
Loss Allowance	1.61	10.49
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	2.83	44.51
Adjustment for:-		
(Increase)/decrease Trade and Other Receivables	(339.07)	73.89
Increase/(decrease) Trade Payables	100.79	(485.06)
Increase/(decrease) Other Current Liabilities	22.58	3.28
(Increase)/decrease in Inventories	83.33	21.34
(Increase)/decrease Others Current Assets	(166.80)	9.66
(Increase)/decrease Current Tax Assets	0.76	-
CASH GENERATED FROM OPERATIONS	(298.41)	(376.89)
Income tax refund / (tax paid)-Net	(4.94)	26.40
Last Year Direct Taxes Paid	0.03	-
I NET CASH FLOW FROM OPERATING ACTIVITIES	(300.49)	(305.99)
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(1.84)	(1.60)
Interest on FD	13.15	2.27
Purchase of Investment	(1,770.85)	-
Proceeds from Sale of Investment	-	33.25
Loans Repayments Received	596.20	5.27
Loans Given	(1,551.39)	(2.66)
Tds on interest to NRI	(151.17)	-
Tds on Interest	(3.38)	-
Interest Income	40.30	-
II NET CASH USED IN INVESTING ACTIVITIES	(2,828.98)	36.33
C CASH FLOW FROM FINANCING ACTIVITIES		
Preceeds from Issue of Share Capital	2,768.80	-
Proceeds from Long Term Borrowings	548.00	304.00
Interest Expenses	(37.45)	5.10
Tds on Interest	-	(0.90)
Repayment of Long Term Borrowing	(567.58)	-
Cash Received from Securities Premium	2,076.45	-
III NET CASH USED IN FINANCING ACTIVITIES	4,788.02	308.20
NET INCREASE/(DECREASE) IN CASH OR CASH EQUIVALENTS (I + II + III)	1,658.55	38.54
Add:- CASH & CASH EQUIVALENTS AS AT BEGNNING	199.31	160.76
CLOSING BALANCE OF CASH & CASH EQUIVALENTS	1,857.86	199.31

For and on behalf of the Board
GENPHARMASEC LIMITED
(FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)

Sohan
Sohan Chaturvedi

(WHOLE TIME DIRECTOR & CFO)
DIN : 09629728



Place: Mumbai
Date :24.05.2024

GENPHARMASEC LIMITED
(Formerly known as Generic Pharmasec Ltd)

"ANNEXURE - I"

Statement of Audited Segment-wise Revenue, Results, Assets and Liabilities for the Quarter & Year Ended 31st March, 2024

(Rs. In Lakhs)

Particulars	Quarter Ended			Year Ended	
	31/03/2024	31/12/2023	31/03/2023	31/03/2024	31/03/2023
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Segment Revenue					
Pharmaceuticals	1,019.85	638.45	715.14	3,040.57	2,528.34
Trading in Securities	-	-	28.73	-	23.23
Total Revenue	1,019.85	638.45	743.86	3,040.57	2,551.57
Segment Results (Profit before tax and interest)					
Pharmaceuticals	130.84	(33.42)	105.56	225.06	195.80
Trading in Securities	(22.90)	21.51	(92.63)	54.28	(94.53)
Total	107.94	(11.92)	12.93	279.35	101.27
Less					
(i) Unallocated Finance Cost	-	-	-	-	-
(ii) Other unallocable expenditure net of unallocable income	(75.28)	14.90	(32.32)	(232.69)	(73.11)
(iii) Inter Segment Eliminations	-	-	-	-	-
Profit Before Tax	32.67	2.98	(19.39)	46.66	28.16
Segment Assets					
Pharmaceuticals	1,835.25	1,068.62	1,483.52	1,835.25	1,483.52
Trading in Securities	126.03	148.94	70.93	126.03	70.93
Un-Allocated	5,086.18	1,083.17	433.08	5,086.18	433.08
Total	7,047.46	2,300.72	1,987.53	7,047.46	1,987.53
Segment Liabilities					
Pharmaceuticals	230.22	84.77	137.72	230.22	137.72
Trading in Securities	-	-	-	-	-
Un-Allocated	6,817.24	2,215.95	1,849.81	6,817.24	1,849.81
Total	7,047.46	2,300.72	1,987.53	7,047.46	1,987.53
	0.00	-	(0.00)	0.00	(0.00)

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments"

For and on behalf of the Board of
Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)

Sohan

Sohan Chaturvedi
(WHOLE TIME DIRECTOR &
CFO)

DIN : 09629728

PLACE : MUMBAI

Date :24.05.2024





Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander (East), Dist – Thane, Maharashtra- 401105

Mob 9029326651, Email: caabhishek2012@gmail.com

INDEPENDENT AUDITOR’S REPORT

To

The Board of Directors

GENPHARMASEC LIMITED

(Formerly known as ‘Generic Pharmasec Limited’)

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying statement of Consolidated financial results of **GENPHARMASEC LIMITED (Formerly known as ‘Generic Pharmasec Limited’)** and its subsidiary (the Company and its subsidiary together referred to as “the Group”) (Refer annexure-1 for the list of entities included in the statement) for the quarter and year ended 31st March, 2024 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”)

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the audit report on separate financial statement of subsidiaries the statements referred to in Other Matters section below, the Consolidated financial results for the quarter and year ended 31st March, 2024:

- (i) Includes the result of the following entity:
 - Clinigenome India Private Limited
 - Genpharmasec Middle East DMCC
- (ii) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (iii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net loss and consolidated total other comprehensive income and other financial information of the Group for the quarter ended as well as for the year to date results for the period from 1.4.2023 to 31.03.2024

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (“the Act”). Our responsibilities under those



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander (East), Dist – Thane, Maharashtra- 401105

Mob 9029326651, Email: caabhishek2012@gmail.com

Standards are further described in the auditor's responsibilities for the audit of the Consolidated financial results section of our report. We are independent of the Group in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Consolidated financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's responsibility for the Consolidated Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Parent's Board of Directors are responsible for the preparation of these consolidated financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ' Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for purpose of preparation of the consolidated financial results by the Directors of the Parent, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's responsibilities for the Audit of the Consolidated financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated financial results.



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander (East), Dist – Thane, Maharashtra- 401105

Mob 9029326651, Email: caabhishek2012@gmail.com

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the operating effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated financial results, including the disclosures, and whether the Consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander (East), Dist – Thane, Maharashtra- 401105

Mob 9029326651, Email: caabhishek2012@gmail.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

- a. The accompanying Statement includes the audited separate financial statements/financial results/financial information, in respect of one subsidiary whose interim financial results reflect total assets of Rs. 152.05 Lakhs and total revenues 'Nil' for the quarter and year ending 31st March, 2024, total net profit/(loss) after tax of Rs. (13.61) Lakhs for the quarter ending 31st March, 2024 and Rs. (13.61) Lakhs for the year ending 31st March, 2024, total comprehensive income/(loss) of Rs. (13.61) Lakhs for the quarter ending 31st March, 2024 and Rs. (13.61) Lakhs for the year ending 31st March, 2024, as considered in the consolidated financial results. These financial information have been audited by us and our opinion and conclusion on the Statement, so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based solely on the such report and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our opinion on the Annual Consolidated Financial Results is not modified in respect of the above matter with respect to our reliance on the work done and the reports of such audit.

- b. The accompanying Statement includes the unaudited standalone financial statements/financial results/financial information, in respect of one subsidiary located outside India whose interim financial results reflect total assets of Rs. 11.37 Lakhs and total revenues 'Nil' for the quarter and year ending 31st March, 2024, total net profit/(loss) after tax of Rs. (8.79) Lakhs for the quarter and year ending 31st March, 2024, total comprehensive income/(loss) of Rs. (8.79) Lakhs for the quarter and year ending 31st March, 2024, as considered in the consolidated financial results. These annual standalone financial statements/ financial results/ financial information are unaudited and have been furnished to us by the Management and our opinion on the Consolidated Financial Results for the Year ended 31st March 2024, in so far as it relates to the amounts and disclosures included in respect of these subsidiary, is based solely on such annual unaudited standalone financial statements/financial results/financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, these standalone financial statements/financial results/financial information are not material to the Group.

Our opinion on the Consolidated Financial Results for the Year ended 31st March 2024 is not modified in respect of the above matter with respect to our reliance on the standalone financial statements/financial results/financial information certified by the Board of Directors.



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander (East), Dist – Thane, Maharashtra- 401105

Mob 9029326651, Email: caabhishek2012@gmail.com

- c. The Statement includes the Consolidated financial results for the quarter ended 31st March, 2024 being the balancing figures between audited figures in respect of the financial year ended 31st March, 2024 and the published unaudited year to date figures upto 31st December, 2023, being the date of the end of the third quarter of the current financial year, which were subject to limited review by us, as required under the Listing Regulations.

For Abhishek S Tiwari & Associates
Chartered Accountants
FRN: 141048W



Abhishek Tiwari
Partner
M.No.155947
Place : Mumbai
Date: 24.05.2024
UDIN: 24155947BKCAXH6458

GENPHARMASEC LIMITED (FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED) Consolidated Statement of Audited Financial Results for the Quarter & Year Ended 31st March, 2024 (Rs. In Lakhs)					
Particulars	Quarter Ended			Year Ended	
	* 31/03/2024	31-12-2023	31/03/2023	* 31/03/2024	31/03/2023
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1 Revenue from Operations	1,019.85	638.45	621.65	3,040.57	2,551.57
2 Other Income	31.15	14.25	5.80	65.59	10.01
3 Total Revenue (1 + 2)	1,051.00	652.71	627.44	3,106.16	2,561.58
4 Expenses					
Cost of materials consumed	-	-	-	-	-
Purchase of stock-in-trade	769.05	393.96	630.14	2,339.92	2,318.40
Changes in inventories of finished goods, work-in-progress and stock-in-trade	50.05	104.62	(99.26)	83.33	21.34
Employee benefits expense	16.21	23.46	18.89	76.42	53.67
Finance Cost	15.67	0.47	5.60	40.91	5.60
Depreciation and amortisation expense	2.97	12.45	0.60	4.21	1.97
Other expenses	185.99	114.78	53.23	536.30	132.45
Total expenses	1,039.94	649.72	607.22	3,081.10	2,533.42
5 Profit/(Loss) Before Exceptional Item and Tax (3-4)	11.06	2.98	20.24	25.06	28.16
6 Exceptional items	-	-	-	-	-
7 Profit/(Loss) Before Tax (5-6)	11.06	2.98	20.24	25.06	28.16
8 Tax expense					
(1) Current Tax	-	-	-	0.03	-
(2) Deferred Tax	(37.81)	3.39	84.32	(42.02)	84.32
(3) Prior Period Tax	-	(0.03)	-	-	-
9 Profit / (Loss) from continuing	(26.75)	6.34	104.56	(16.93)	112.48
10 Profit / (Loss) from discontinuing operations	-	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-	-
12 Profit/(loss) from Discontinuing	-	-	-	-	-
13 Profit (Loss) for the period (9+12)	(26.75)	6.34	104.56	(16.93)	112.48
(a) Owners of the Parent	(12.56)	-	-	(12.56)	-
(b) Non controlling Interests	(4.37)	-	-	(4.37)	-
14 Other Comprehensive income;					
A (i) Items that will not be reclassified to profit or loss					
Equity Instruments through FVOCI					
(a) Owners of the Parent	101.91	28.87	(14.32)	(73.04)	(116.40)
(b) Non controlling Interests	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss					
(a) Owners of the Parent	-	-	-	-	-
(b) Non controlling Interests	-	-	-	-	-
15 Total Comprehensive Income for the period (13+14) (Comprising profit/(loss) and other Comprehensive	75.16	35.21	90.24	(89.97)	(3.92)
(a) Owners of the Parent	89.35	28.87	(14.32)	(85.60)	(116.40)
(b) Non controlling Interests	(4.37)	-	-	(4.37)	-
16 Paid-up Equity Share Capital (Face value of equity share is Rs.1/- each)	5,537.20	2,768.60	2,768.60	5,537.20	2,768.60
17 Other Equity				902.35	(1,235.56)

18	Earnings per equity share (for discontinued & continuing operations) of face value of Rs. 10 each					
	(a) Basic	(0.00)	0.00	0.04	(0.00)	0.04
	(b) Diluted	(0.00)	0.00	0.04	(0.00)	0.04

* The Company has invested in its subsidiaries in the quarter ended 31.03.2024 the figures for the quarter and year ended 31.03.2024 for the consolidated holdings

Notes:

- 1 The Financial result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 24th May, 2024.
- 2 The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.
- 3 The audited report does not contain any qualification. The above Financial audited review report will be filed with the stock Exchange and will also be available on Company's website www.genpharmasec.com
- 4 Segment Reporting has been annexed in Annexure 1.
- 5 The certificate of CFO in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the above results has been placed before the Board of Directors
- 6 The outstanding loan of Rs. 41.96 Lacs as on 31.03.24, have been provided as bad debts by the company and is included under the head 'Other Expenses' for the quarter and year ended 31.3.24.
- 7 The results for the quarter ended 31st March,2024 and 31st March,2023 are the balancing figure between audited figures in respect of the full financial year and the published unaudited financial results of the nine months ended 31st December ,2023 and 31st December,2022 respectively.
- 8 The Name of the company has been changed from Generic Pharmasec Limited to Genpharmasec Limited w.e.f 25th October,2021
- 9 The company has incorporated a new wholly owned subsidiary namely M/s. Clinigenome India Pvt Ltd' to expand the business activities on 29.01.2024
- 10 The Company has recognised the Deferred Tax Assets of Rs. 42.50 Lacs on Carried forward unabsorbed Depreciation Loss of Rs.184.50 Lacs as per income tax records on the bases of managemnet estimate of virtual certainty of Profit in future.
- 11 During the quarter ended 31st March, 2024; the company made investment in M/s. Derren Healthcare Pvt Ltd, (DHPL) as detailed hereunder:

The Company has entered into a Share Purchase Agreement (SPA) with DHPL and its promoters on 19th September 2023 for acquiring 70% shareholding of DHPL. The Company has also simultaneously entered into a Share Subscription Cum Shareholder's Agreement' (SSSA) on the same day to and agreed to induct Rs. 5 Crores Into DHPL and in turn, DHPL will allot 13,84,275 shares to the Company.

The Company made payment of Rs. 12,63,95,377/- to one of the Promoters, Mr. Vibhava Kumar Singh who is holding 70% shares in DHPL for purchase of 35,00,000 shares. The Company has also inducted Rs. 5 crore in DHPL for subscription of 13,84,275 shares. These payments represent full payment towards total acquisition of 70% shareholding in DHPL and additional shareholding as envisaged in SSSA.

The total acquisition is to be completed by 19th September 2024. However, M/s. Genpharmasec Ltd, the company, will gain 'controlling interest' only after complete execution of respective SPA and SSA.
- 12 The Board of Directors at its meeting held on 21st February 2024 allotted 27,68,59,850 shares to the Equity Shareholders of the Company through Right issue at issue price of Rs. 1.75 per equity Share (including a premium of Rs. 0.75 per equity Share).

The company has incorporated a subsidiary namely, M/s Genpharmasec Middle East DMCC in Dubai vide Certificate of Incorporation No. DMCC197026 and obtained a Trading License No. DMCC - 887983 dated 13th July 2023 for trading of medical Surgical Equipment, Instruments, Articles, Medical Gas and Food Supplements. The company stake is 52% in the said subsidiary. the subscription amount AED 26,000/- transferred to Bank of Baroda on 28 march 2024.

For and on behalf of the Board of
Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)

Sohan

Sohan Chaturvedi
(WHOLE TIME DIRECTOR & CFO)
DIN : 09629728

PLACE : MUMBAI
Date :24.05.2024



GENPHARMASEC LIMITED
(FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)
Consolidated Statement of Audited Assets & Liability as at 31st March, 2024
(Amount in Lakhs)

Particulars	* As At 31st March 2024	As At 31st March 2023
Assets		
(1) Non-Current Assets		
(A) Property, Plant And Equipment	83.90	10.00
(B) Financial Assets	-	-
(i) Investments	1,776.79	-
(ii) Loans	1,124.72	-
(iii) Others	-	-
(C) Deferred Tax Asset (Net)	42.60	84.61
Total Non-Current Assets	3,028.01	94.61
(2) Current Assets		
(A) Inventories	684.22	967.55
(B) Financial Assets	-	-
(i) Investments	168.39	95.35
(ii) Trade Receivables	909.99	570.92
(iii) Cash And Cash Equivalents	316.98	39.76
(iv) Bank Balance Other Than (ii) Above	1,566.20	159.55
(v) Loans	0.69	48.13
(C) Current Tax Assets (Net)	4.94	0.76
(D) Other Current Asset	233.17	10.90
Total Current Assets	4,084.57	1,892.92
Total Assets	7,112.58	1,987.53
Equity And Liabilities		
Equity		
Equity attributable to owners of the Parents		
(A) Equity Share Capital	5,537.20	2,768.60
(B) Other Equity	902.35	(1,235.56)
Equity attributable to non-controlling interests		
(A) Equity Share Capital	18.32	-
(B) Other Equity	(4.37)	-
Total Of Equity	6,453.49	1,533.04
Liabilities		
(1) Non-Current Liabilities		
(A) Financial Liabilities		
(i) Borrowings	321.04	248.12
(ii) Lease Liability	67.83	-
(D) Other Non-Current Liabilities	-	-
Total Non-Current Liabilities	388.87	248.12
(2) Current Liabilities		
(A) Financial Liabilities		
(i) Borrowings	-	80.08
(ii) Trade Payables	-	-
A) Total Outstanding Dues Of Micro Enterprises And Small E	11.75	-
B) Total Outstanding Dues Of Creditors Other Than Micro E	226.18	137.00
(B) Other Current Liabilities	32.29	9.29
Total Current Liabilities	270.22	206.37
Total Equity And Liabilities	7,112.58	1,987.53



* The Company has invested in its subsidiaries in the quarter ended 31.03.2024 the figures for the quarter and year ended 31.03.2024 are the consolidated holdings

For and on behalf of the Board
GENPHARMASEC LIMITED
(FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)

Sohan
Sohan Chaturvedi
(WHOLE TIME DIRECTOR & CFO)
DIN : 09629728



Place: Mumbai
Date :24.05.2024

GENPHARMASEC LIMITED		
(FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)		
Consolidated Cash Flow Statement for the year ended 31st March, 2024		
(Amount in Lakhs)		
PARTICULARS	*For the year ended 31st March 2024	For the year ended 31st March 2023
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit/(Loss) before tax and Extra Ordinary items	25.06	28.16
Adjustment for:-		
Depreciation	4.21	1.97
FVOCI	(73.04)	-
Interest Expenses	38.90	-
Interest Income	(34.13)	-
Interest on FD measured at Amortised cost	(13.15)	(2.27)
Interest Income on income tax refund	(0.03)	(0.80)
Baddebts	41.96	6.97
Loss Allowance	0.78	10.49
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	(52.18)	44.51
Adjustment for:-		
(Increase)/decrease Trade and Other Receivables	(339.07)	73.89
Increase/(decrease) Trade Payables	100.93	(485.06)
Increase/(decrease) Other Current Liabilities	23.00	3.28
(Increase)/decrease in Inventories	83.33	21.34
(Increase)/decrease Others Current Assets	(222.28)	9.66
(Increase)/decrease Current Tax Assets	0.76	-
CASH GENERATED FROM OPERATIONS	(353.32)	(376.89)
Income tax refund / (tax paid)-Net	(4.94)	26.40
Last Year Direct Taxes Paid	0.03	-
I NET CASH FLOW FROM OPERATING ACTIVITIES	(410.40)	(305.99)
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	1.84	(1.60)
Interest on FD	13.15	2.27
Purchase of Investment	(1,763.96)	-
Proceeds from Sale of Investment	-	33.25
Loans Repayments Received	596.20	5.27
Loans Given	(1,461.39)	(2.86)
Tds on interest to NRI	(151.17)	-
Tds on Interest	(3.38)	-
Interest Income	34.13	-
II NET CASH USED IN INVESTING ACTIVITIES	(2,734.59)	36.33
C CASH FLOW FROM FINANCING ACTIVITIES		
Preceeds from Issue of Share Capital	2,768.60	-
Proceeds from Long Term Borrowings	548.00	304.00
Interest Expenses	(38.90)	5.10
Tds on Interest	-	(0.90)
Repayment of Long Term Borrowing	(568.02)	-
Cash Received from Securities Premium	2,076.45	-
III NET CASH USED IN FINANCING ACTIVITIES	4,786.13	308.20
NET INCREASE/(DECREASE) IN CASH OR CASH EQUIVALENTS (I + II + III)	1,683.86	38.54
Add:- CASH & CASH EQUIVALENTS AS AT BEGNNING	199.31	160.76
CLOSING BALANCE OF CASH & CASH EQUIVALENTS	1,883.17	199.31
* The Company has invested in its subsidiaries in the quarter ended 31.03.2024 the figures for the quarter and year ended 31.03.2024 are the consolidated holdings		
For and on behalf of the Board, GENPHARMASEC LIMITED (FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)		
 Sohan Chaturvedi		
(WHOLE TIME DIRECTOR & CFO) DIN : 09629728		
		
Place: Mumbai		
Date :24.05.2024		

GENPHARMASEC LIMITED
(Formerly known as Generic Pharmasec Ltd)

"ANNEXURE - I"

Consolidated Statement of Audited Segment-wise Revenue, Results, Assets and Liabilities for the Quarter & Year Ended 31st March, 2024

(Rs. In Lakhs)

Particulars	Quarter Ended			Year Ended	
	* 31/03/2024	31/12/2023	31/03/2023	* 31/03/2024	31/03/2023
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Segment Revenue					
Pharmaceuticals	1,019.85	638.45	715.14	3,040.57	2,528.34
Trading in Securities	-	-	28.73	-	23.23
Total Revenue	1,019.85	638.45	743.86	3,040.57	2,551.57
Segment Results (Profit before tax and interest)					
Pharmaceuticals	152.23	(33.42)	105.56	224.56	195.80
Trading in Securities	(22.90)	21.51	(92.63)	54.28	(94.53)
Total	129.33	(11.92)	12.93	278.85	101.27
Less					
(i) Unallocated Finance Cost	-	-	-	-	-
(ii) Other unallocable expenditure net of unallocable income	(118.27)	14.90	(32.32)	(253.79)	(73.11)
(iii) Inter Segment Eliminations	-	-	-	-	-
Profit Before Tax	11.06	2.98	(19.39)	25.06	28.16
Segment Assets					
Pharmaceuticals	1,881.00	1,068.62	1,483.52	1,881.00	1,483.52
Trading in Securities	126.03	148.94	70.93	126.03	70.93
Un-Allocated	5,105.55	1,083.17	433.08	5,105.55	433.08
Total	7,112.58	2,300.72	1,987.53	7,112.58	1,987.53
Segment Liabilities					
Pharmaceuticals	230.22	84.77	137.72	230.22	137.72
Trading in Securities	-	-	-	-	-
Un-Allocated	6,882.35	2,215.95	1,849.81	6,882.35	1,849.81
Total	7,112.58	2,300.72	1,987.53	7,112.58	1,987.53
	(0.00)	-	(0.00)	(0.00)	(0.00)

* The Company has invested in its subsidiaries in the quarter ended 31.03.2024 the figures for the quarter and year ended 31.03.2024 are the consolidated holdings

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments"

For and on behalf of the Board of
Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)

Sohan

Sohan Chaturvedi
(WHOLE TIME DIRECTOR &
CFO)

DIN : 09629728

PLACE : MUMBAI

Date : 24.05.2024



Date: 24.05.2024

To,
BSE Limited
The Compliance Department of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 531592

Dear Sir/ Madam,

Subject: Declaration pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (LODR) Regulations, 2015.

In terms of provision of Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, we hereby declare that the Statutory Auditors of the Company M/S. Abhishek S. Tiwari & Associates, Chartered Accountants, have issued an Audit Report with Unmodified Opinion on Standalone & Consolidated Audited Financial Results of the Company for the Quarter and Financial year ended 31st March, 2024.

Kindly take the same on records for your perusal.

Thanking you,

Yours faithfully,

For and behalf of the Board of Director of,
Genpharmasec Limited

SOHAN
CHATURVEDI

Digitally signed by
SOHAN CHATURVEDI
Date: 2024.05.24
23:20:15 +05'30'



Mr. Sohan Chaturvedi
Whole time director & CFO
DIN- 09629728